COSM · Cosmos Health Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of 12 months from the date of this filing.”View the 10-Q filed Aug 18, 2026
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Contract manufacturing production pipeline | 32.7M | current (date of release) | — |
| Pharmacies in distribution network | 1,500 | current (date of release) | — |
| Adjusted gross margin non-GAAP | 9.54% | Q2 2026 | — |
| Adjusted Gross Profit non-GAAP | $3,695,361 | Six Months Ended June 30, 2026 | — |
| Adjusted Revenue non-GAAP | $37,716,796 | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Distribution — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COSM
this stock
Cosmos Health Inc.
|
$33.26M | -33.6% | +19.9% | — | 2.5% |
|
MCK
Mckesson Corp
|
$117.81B | +25.6% | +3.1% | 27.1 | 2.0% |
|
COR
Cencora, Inc.
|
$65.51B | +1.6% | +9.3% | 25.5 | 2.1% |
|
CAH
Cardinal Health Inc
|
$59.90B | +25.3% | +14.2% | — | 3.2% |
|
HSIC
Henry Schein Inc
|
$9.36B | +12.0% | +5.9% | 24.5 | 7.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COSM | -13.7% | -6.6% | -7.7% | -23.1% | -33.6% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -12.5% | -6.1% | -15.8% | -24.0% | -46.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.